These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 36576563)

  • 1. SGLT-2 inhibitors and euglycemic diabetic ketoacidosis/diabetic ketoacidosis in FAERS: a pharmacovigilance assessment.
    He Z; Lam K; Zhao W; Yang S; Li Y; Mo J; Gao S; Liang D; Qiu K; Huang M; Wu J
    Acta Diabetol; 2023 Mar; 60(3):401-411. PubMed ID: 36576563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes Mellitus Receiving Oral Therapy.
    Dull RB; Spangler ML; Knezevich EL; Lau BM
    J Pharm Pract; 2019 Apr; 32(2):240-243. PubMed ID: 29241389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort.
    Ata F; Yousaf Z; Khan AA; Razok A; Akram J; Ali EAH; Abdalhadi A; Ibrahim DA; Al Mohanadi DHSH; Danjuma MI
    Sci Rep; 2021 May; 11(1):10293. PubMed ID: 33986421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium glucose co-transporter-2 inhibitor-induced diabetic ketoacidosis following tooth extraction: improving awareness among dental practitioners.
    Yap SD; Hamblin PS; Bach L; Ekinci E; Wong R
    Aust Dent J; 2021 Dec; 66(4):444-447. PubMed ID: 34432892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of sodium glucose co-transporter-2 inhibitors with risk of diabetic ketoacidosis among hospitalized patients: A multicentre cohort study.
    Sarma S; Hodzic-Santor B; Raissi A; Colacci M; Verma AA; Razak F; Højbjerg Lassen MC; Fralick M
    J Diabetes Complications; 2024 Sep; 38(9):108827. PubMed ID: 39096768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis; from Pathophysiology to Clinical Practice.
    Patoulias D; Manafis A; Mitas C; Avranas K; Lales G; Zografou I; Sambanis C; Karagiannis A
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):139-146. PubMed ID: 29412120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A series of diabetic ketoacidosis associated with the use of sodium-glucose co-transporter-2 inhibitors in secondary care.
    Taverner S; Eng C; Watson R; George S; Edwards A; Williams DM; Stephens JW
    Diabetes Metab Syndr; 2022 Dec; 16(12):102658. PubMed ID: 36371968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Euglycaemic diabetic ketoacidosis as a complication of SGLT-2 inhibitors: epidemiology, pathophysiology, and treatment.
    Sampani E; Sarafidis P; Papagianni A
    Expert Opin Drug Saf; 2020 Jun; 19(6):673-682. PubMed ID: 32521174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGLT-2i associated diabetic ketoacidosis in the setting of cardiogenic shock.
    Guzner A; Downs I; Cruz D; Kaneshiro C; Donangelo I
    BMJ Case Rep; 2024 Sep; 17(9):. PubMed ID: 39242124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review.
    Bamgboye AO; Oni IO; Collier A
    Eur J Clin Pharmacol; 2021 May; 77(5):651-657. PubMed ID: 33244632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus: A case report.
    Lee IH; Ahn DJ
    Medicine (Baltimore); 2020 May; 99(21):e20228. PubMed ID: 32481295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperglycemic, high anion-gap metabolic acidosis in patients receiving SGLT-2 inhibitors for diabetes management.
    Kum-Nji JS; Gosmanov AR; Steinberg H; Dagogo-Jack S
    J Diabetes Complications; 2017 Mar; 31(3):611-614. PubMed ID: 27913012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin: case report and literature review.
    Sampani E; Sarafidis P; Dimitriadis C; Kasimatis E; Daikidou D; Bantis K; Papanikolaou A; Papagianni A
    BMC Nephrol; 2020 Jul; 21(1):276. PubMed ID: 32669085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes Mellitus.
    Chauhan S; Manov A; Dhillon GS; Shah P
    Cureus; 2023 Jan; 15(1):e33892. PubMed ID: 36819400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis : A Multicenter Cohort Study.
    Douros A; Lix LM; Fralick M; Dell'Aniello S; Shah BR; Ronksley PE; Tremblay É; Hu N; Alessi-Severini S; Fisher A; Bugden SC; Ernst P; Filion KB;
    Ann Intern Med; 2020 Sep; 173(6):417-425. PubMed ID: 32716707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "The Bitter Truth of Sugar"-Euglycemic Diabetic Ketoacidosis due to Sodium-glucose Cotransporter-2 Inhibitors: A Case Series.
    Shah M; Pathrose E; Bhagwat NM; Chandy D
    Indian J Crit Care Med; 2022 Jan; 26(1):123-126. PubMed ID: 35110855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials.
    Monami M; Nreu B; Zannoni S; Lualdi C; Mannucci E
    Diabetes Res Clin Pract; 2017 Aug; 130():53-60. PubMed ID: 28570924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Normal but Catastrophic" Euglycemic Diabetic Ketoacidosis Precipitated by Sodium-Glucose Cotransporter-2 Inhibitor Use: A Case Report.
    Sarno MJF; Hernandez DPF; Matulac MO
    Cureus; 2023 Nov; 15(11):e49236. PubMed ID: 38143642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Severe SGLT-2 inhibitor-induced euglycemic ketoacidosis-a rare but serious complication].
    Rotsel E; Pietsch U
    Anaesthesist; 2020 Jan; 69(1):49-51. PubMed ID: 31807797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacovigilance study for SGLT 2 inhibitors- Safety review of real-world data & randomized clinical trials.
    Bhanushali KB; Asnani HK; Nair A; Ganatra S; Dani SS
    Curr Probl Cardiol; 2024 Sep; 49(9):102664. PubMed ID: 38789017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.